10-KPeriod: FY2023

BIOGEN INC. Annual Report, Year Ended Dec 31, 2023

Filed February 14, 2024For Securities:BIIB

Summary

Biogen Inc.'s 2023 10-K filing highlights a year marked by significant strategic moves, including the substantial acquisition of Reata Pharmaceuticals for approximately $6.6 billion, which brought SKYCLARYS for Friedreich's Ataxia into their portfolio. This acquisition, alongside other product launches like QALSODY for ALS and ZURZUVAE for postpartum depression, signals a strategic pivot towards rare diseases and neurology, particularly in Alzheimer's disease with the traditional FDA approval and expanded coverage for LEQEMBI. However, the company faces considerable headwinds, most notably a significant decline in revenue from its Multiple Sclerosis (MS) franchise, driven by increased competition from generics and biosimilars, particularly impacting TECFIDERA. This decline is a major concern for investors, as the MS segment has historically been a core revenue driver. Despite these challenges, Biogen is implementing a "Fit for Growth" program aimed at achieving significant cost savings by 2025. The company's financial health remains robust, supported by a strong cash position, though reduced significantly by the Reata acquisition, and the absence of share repurchases in 2023.

Financial Highlights

54 data points
Beta

Revenue

$9.84B

74.2% Gross Margin

Net Income

$1.16B

11.8% Net Margin

EPS (Diluted)

$7.97

Total Assets

$26.84B

Cash & Equivalents

$1.05B

Free Cash Flow

$1.27B

Financial Statements
Beta
Revenue$9.84B
Cost of Revenue$2.53B
Gross Profit$7.30B
SG&A Expenses$2.55B
Operating Expenses$8.54B
Interest Expense$246.90M
Net Income$1.16B
EPS (Basic)$8.02
EPS (Diluted)$7.97
Shares Outstanding (Basic)144.70M
Shares Outstanding (Diluted)145.60M

Key Highlights

  • 1Acquisition of Reata Pharmaceuticals for approximately $6.6 billion, adding SKYCLARYS for Friedreich's Ataxia.
  • 2LEQEMBI received traditional FDA approval for Alzheimer's disease, leading to broader CMS coverage, and launched in Japan and China.
  • 3QALSODY for ALS and ZURZUVAE for postpartum depression were launched in the US, expanding the rare disease and neurology portfolios.
  • 4Significant revenue decline in the Multiple Sclerosis (MS) franchise, primarily due to generic competition for TECFIDERA and market shifts to higher efficacy therapies for interferons.
  • 5Implementation of the "Fit for Growth" program aiming for $1.0 billion in gross operating expense savings by 2025, including an estimated 1,000 net headcount reductions.
  • 6No share repurchases were made in 2023, with approximately $2.1 billion remaining under the 2020 Share Repurchase Program.
  • 7Cash, cash equivalents, and marketable securities decreased significantly to approximately $1.0 billion from $5.6 billion due to the Reata acquisition funding.

Frequently Asked Questions

Biogen experienced a 3.3% decrease in total revenue to $9.8 billion, primarily driven by a 9.3% drop in product revenue. This decline is largely attributable to the MS franchise, which saw a 14.1% decrease, mainly due to generic competition for TECFIDERA and patient shifts to newer therapies. Conversely, rare disease revenue saw a slight increase due to SKYCLARYS, and biosimilar revenue also grew modestly. Total costs and expenses increased by 29.7%, significantly impacted by acquisition-related expenses and clinical trial close-outs.

The acquisition of Reata for approximately $6.6 billion strengthens Biogen's rare disease and neurology portfolio with the addition of SKYCLARYS, the first treatment for Friedreich's Ataxia in the US and EU. This strategic move diversifies Biogen's revenue streams beyond its declining MS business. However, the acquisition also significantly reduced Biogen's cash reserves and incurred substantial acquisition and integration costs, which impacted earnings in 2023.

The MS franchise faces intense competition from generics and biosimilars, particularly for TECFIDERA, leading to significant revenue declines. Additionally, patients are increasingly moving towards higher-efficacy therapies, impacting sales of older treatments like interferons. The emergence of a TYSABRI biosimilar also presents a future competitive threat. Biogen expects continued revenue decline in this segment.

Biogen is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Key growth drivers include the successful commercialization of LEQEMBI for Alzheimer's disease, the continued rollout of SKYCLARYS for Friedreich's Ataxia, and the potential of ZURZUVAE for postpartum depression. The company is also exploring strategic options for its biosimilars business and is committed to internal R&D and external collaborations.